The global demulcent eye drops market size is evaluated at USD 2.19 billion in 2025 and is forecasted to hit around USD 4.09 billion by 2034, growing at a CAGR of 7.86% from 2025 to 2034. The North America market size was accounted at USD 703.61 million in 2024 and is expanding at a CAGR of 7.94% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Demulcent Eye Drops Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Demulcent Eye Drops Market Revenue and Volume Forecast, by Active Pharmaceutical Ingredient Type
8.1.1. Cellulose Derivatives
8.1.1.1. Market Revenue and Volume Forecast
8.1.2. Dextran 70
8.1.2.1. Market Revenue and Volume Forecast
8.1.3. Polyols
8.1.3.1. Market Revenue and Volume Forecast
8.1.4. Polymers
8.1.4.1. Market Revenue and Volume Forecast
8.1.5. Others
8.1.5.1. Market Revenue and Volume Forecast
9.1. Demulcent Eye Drops Market Revenue and Volume Forecast, by Drug Formulation
9.1.1. Preservative Based
9.1.1.1. Market Revenue and Volume Forecast
9.1.2. Non-preservative Based
9.1.2.1. Market Revenue and Volume Forecast
10.1. Demulcent Eye Drops Market Revenue and Volume Forecast, by Medication Type
10.1.1. Over-the-counter (OTC)
10.1.1.1. Market Revenue and Volume Forecast
10.1.2. Prescription
10.1.2.1. Market Revenue and Volume Forecast
11.1. Demulcent Eye Drops Market Revenue and Volume Forecast, by Distribution Channel
11.1.1. Hospital Pharmacies
11.1.1.1. Market Revenue and Volume Forecast
11.1.2. Retail Pharmacies
11.1.2.1. Market Revenue and Volume Forecast
11.1.3. Online Pharmacies
11.1.3.1. Market Revenue and Volume Forecast
12.1. North America
12.1.1. Market Revenue and Volume Forecast, by Active Pharmaceutical Ingredient Type
12.1.2. Market Revenue and Volume Forecast, by Drug Formulation
12.1.3. Market Revenue and Volume Forecast, by Medication Type
12.1.4. Market Revenue and Volume Forecast, by Distribution Channel
12.1.5. U.S.
12.1.5.1. Market Revenue and Volume Forecast, by Active Pharmaceutical Ingredient Type
12.1.5.2. Market Revenue and Volume Forecast, by Drug Formulation
12.1.5.3. Market Revenue and Volume Forecast, by Medication Type
12.1.5.4. Market Revenue and Volume Forecast, by Distribution Channel
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Volume Forecast, by Active Pharmaceutical Ingredient Type
12.1.6.2. Market Revenue and Volume Forecast, by Drug Formulation
12.1.6.3. Market Revenue and Volume Forecast, by Medication Type
12.1.6.4. Market Revenue and Volume Forecast, by Distribution Channel
12.2. Europe
12.2.1. Market Revenue and Volume Forecast, by Active Pharmaceutical Ingredient Type
12.2.2. Market Revenue and Volume Forecast, by Drug Formulation
12.2.3. Market Revenue and Volume Forecast, by Medication Type
12.2.4. Market Revenue and Volume Forecast, by Distribution Channel
12.2.5. UK
12.2.5.1. Market Revenue and Volume Forecast, by Active Pharmaceutical Ingredient Type
12.2.5.2. Market Revenue and Volume Forecast, by Drug Formulation
12.2.5.3. Market Revenue and Volume Forecast, by Medication Type
12.2.5.4. Market Revenue and Volume Forecast, by Distribution Channel
12.2.6. Germany
12.2.6.1. Market Revenue and Volume Forecast, by Active Pharmaceutical Ingredient Type
12.2.6.2. Market Revenue and Volume Forecast, by Drug Formulation
12.2.6.3. Market Revenue and Volume Forecast, by Medication Type
12.2.6.4. Market Revenue and Volume Forecast, by Distribution Channel
12.2.7. France
12.2.7.1. Market Revenue and Volume Forecast, by Active Pharmaceutical Ingredient Type
12.2.7.2. Market Revenue and Volume Forecast, by Drug Formulation
12.2.7.3. Market Revenue and Volume Forecast, by Medication Type
12.2.7.4. Market Revenue and Volume Forecast, by Distribution Channel
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Volume Forecast, by Active Pharmaceutical Ingredient Type
12.2.8.2. Market Revenue and Volume Forecast, by Drug Formulation
12.2.8.3. Market Revenue and Volume Forecast, by Medication Type
12.2.8.4. Market Revenue and Volume Forecast, by Distribution Channel
12.3. APAC
12.3.1. Market Revenue and Volume Forecast, by Active Pharmaceutical Ingredient Type
12.3.2. Market Revenue and Volume Forecast, by Drug Formulation
12.3.3. Market Revenue and Volume Forecast, by Medication Type
12.3.4. Market Revenue and Volume Forecast, by Distribution Channel
12.3.5. India
12.3.5.1. Market Revenue and Volume Forecast, by Active Pharmaceutical Ingredient Type
12.3.5.2. Market Revenue and Volume Forecast, by Drug Formulation
12.3.5.3. Market Revenue and Volume Forecast, by Medication Type
12.3.5.4. Market Revenue and Volume Forecast, by Distribution Channel
12.3.6. China
12.3.6.1. Market Revenue and Volume Forecast, by Active Pharmaceutical Ingredient Type
12.3.6.2. Market Revenue and Volume Forecast, by Drug Formulation
12.3.6.3. Market Revenue and Volume Forecast, by Medication Type
12.3.6.4. Market Revenue and Volume Forecast, by Distribution Channel
12.3.7. Japan
12.3.7.1. Market Revenue and Volume Forecast, by Active Pharmaceutical Ingredient Type
12.3.7.2. Market Revenue and Volume Forecast, by Drug Formulation
12.3.7.3. Market Revenue and Volume Forecast, by Medication Type
12.3.7.4. Market Revenue and Volume Forecast, by Distribution Channel
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Volume Forecast, by Active Pharmaceutical Ingredient Type
12.3.8.2. Market Revenue and Volume Forecast, by Drug Formulation
12.3.8.3. Market Revenue and Volume Forecast, by Medication Type
12.3.8.4. Market Revenue and Volume Forecast, by Distribution Channel
12.4. MEA
12.4.1. Market Revenue and Volume Forecast, by Active Pharmaceutical Ingredient Type
12.4.2. Market Revenue and Volume Forecast, by Drug Formulation
12.4.3. Market Revenue and Volume Forecast, by Medication Type
12.4.4. Market Revenue and Volume Forecast, by Distribution Channel
12.4.5. GCC
12.4.5.1. Market Revenue and Volume Forecast, by Active Pharmaceutical Ingredient Type
12.4.5.2. Market Revenue and Volume Forecast, by Drug Formulation
12.4.5.3. Market Revenue and Volume Forecast, by Medication Type
12.4.5.4. Market Revenue and Volume Forecast, by Distribution Channel
12.4.6. North Africa
12.4.6.1. Market Revenue and Volume Forecast, by Active Pharmaceutical Ingredient Type
12.4.6.2. Market Revenue and Volume Forecast, by Drug Formulation
12.4.6.3. Market Revenue and Volume Forecast, by Medication Type
12.4.6.4. Market Revenue and Volume Forecast, by Distribution Channel
12.4.7. South Africa
12.4.7.1. Market Revenue and Volume Forecast, by Active Pharmaceutical Ingredient Type
12.4.7.2. Market Revenue and Volume Forecast, by Drug Formulation
12.4.7.3. Market Revenue and Volume Forecast, by Medication Type
12.4.7.4. Market Revenue and Volume Forecast, by Distribution Channel
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Volume Forecast, by Active Pharmaceutical Ingredient Type
12.4.8.2. Market Revenue and Volume Forecast, by Drug Formulation
12.4.8.3. Market Revenue and Volume Forecast, by Medication Type
12.4.8.4. Market Revenue and Volume Forecast, by Distribution Channel
12.5. Latin America
12.5.1. Market Revenue and Volume Forecast, by Active Pharmaceutical Ingredient Type
12.5.2. Market Revenue and Volume Forecast, by Drug Formulation
12.5.3. Market Revenue and Volume Forecast, by Medication Type
12.5.4. Market Revenue and Volume Forecast, by Distribution Channel
12.5.5. Brazil
12.5.5.1. Market Revenue and Volume Forecast, by Active Pharmaceutical Ingredient Type
12.5.5.2. Market Revenue and Volume Forecast, by Drug Formulation
12.5.5.3. Market Revenue and Volume Forecast, by Medication Type
12.5.5.4. Market Revenue and Volume Forecast, by Distribution Channel
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Volume Forecast, by Active Pharmaceutical Ingredient Type
12.5.6.2. Market Revenue and Volume Forecast, by Drug Formulation
12.5.6.3. Market Revenue and Volume Forecast, by Medication Type
12.5.6.4. Market Revenue and Volume Forecast, by Distribution Channel
13.1. Johnson and Johnson Services Inc.
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Alcon Inc., OASIsMedical
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Allegan(Abbvie inc)
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Prestige Consumer Healthcare lnc
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Santen Pharmaceutical Co.Ltd.
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Bausch Health Companies lnc.
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Aurolab, Otsuka Pharmaceutical Co.,ltd.
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Sentiss Pharma Pt. Ltd.
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Sun PharmaceuticalIndustries Ltd.
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. URSAPHARM Arzneimittel GmbH
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample